MarketPulse

drug delivery

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

iDEL Therapeutics Names Ulbrich as Board Chair, Secures €9M Seed Round

iDEL Therapeutics appoints Dr. Claudia Ulbrich as Board Chair and secures €9M seed funding led by BiomedVC to advance its novel cancer drug delivery platform.
NVObiotechclinical development
BenzingaBenzinga··Na

Embecta to Acquire UK Drug-Delivery Specialist Owen Mumford for Up to £150M

Embecta agrees to acquire Owen Mumford Holdings for up to £150M, diversifying beyond insulin delivery into broader drug-delivery technologies.
EMBCacquisitionmanufacturing
BenzingaBenzinga··Vandana Singh

Aptar Promotes Insider Touya to CEO, Signaling Strategic Continuity Amid Mixed Signals

AptarGroup appoints Gael Touya as new CEO, replacing retiring Stephan Tanda. The internal promotion signals strategic continuity but stock shows mixed technical indicators.
ATRtechnical analysisleadership transition
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Eupraxia Raises $63.2M, Eyes 2028 as Cash-Runway Extends Despite Rising Losses

Eupraxia Pharmaceuticals closed $63.2M offering, boosting cash to $80.5M with runway through H2 2028. Q4 losses doubled to $16.7M amid clinical progress in eosinophilic esophagitis treatment.
EPRXpublic offeringdrug delivery
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Novo Nordisk Licenses Vivtex Technology for Oral Obesity and Diabetes Treatments

Novo Nordisk licenses Vivtex's oral drug-delivery technology for obesity and diabetes treatments, with potential $2.1B in milestone payments to develop oral alternatives to injectable biologics.
NVOpartnershipobesity treatment
BenzingaBenzinga··Globe Newswire

Eupraxia Pharmaceuticals Completes $63.2M Offering to Fund GI Disease Pipeline

Eupraxia Pharmaceuticals raises $63.2M to advance its GI disease pipeline, including EP-104GI trials for eosinophilic esophagitis and other gastrointestinal indications.
EPRXclinical trialspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Eupraxia Pharmaceuticals Raises $55M Through Public Offering to Fund GI Pipeline

Eupraxia Pharmaceuticals raises $55M via public offering to advance EP-104GI for eosinophilic esophagitis through Phase 2/3 development and expand GI pipeline.
EPRXclinical trialspublic offering